/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES/
QUEBEC CITY, Nov. 23, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Corporation") (TSXV: OPS) (OTCQX: OPSSF) is
pleased to announce that it has amended the terms of its previously
announced marketed offering (the "Offering") of common shares (the
"Shares") to increase the size of the Offering to approximately
$13,000,500. The Corporation will
file an amended and restated preliminary short form prospectus to
reflect this upsize and provide additional details concerning the
Offering. The Corporation will offer up to 8,667,000 Shares at a
price of $1.50 per Share for maximum
gross proceeds of approximately $13,000,500. The Offering will be conducted on a
best effort basis through Paradigm Capital Inc. ("Paradigm"),
acting as lead agent, and including RBC Capital Markets and
M Partners Inc. (collectively with Paradigm, the
"Agents").
The Corporation has agreed to grant the Agents an option to
cover over-allotments and for market stabilization purposes (the
"Over-Allotment Option"), which will allow the Agents to arrange
for purchasers to acquire up to an additional 1,300,000 Shares sold
under the Offering. The Over-Allotment Option will be exercisable,
in whole or in part, at any time up to 30 days after the closing of
the Offering.
The Offering is being made pursuant to a short form prospectus
filed in each of the provinces of
Quebec, Ontario, Alberta and British Columbia.
A copy of the amended and restated preliminary short form
prospectus will be available on SEDAR at www.sedar.com.
The Offering is expected to close on or about December 8, 2016 and is subject to certain
customary conditions and regulatory approvals, including the
approval of the TSX Venture Exchange and the entering into by the
Corporation and the Agents of an agency agreement.
This press release does not constitute an offer of securities
for sale in the United States or to "U.S. persons" ("U.S.
persons"), as such term is defined in Regulation S promulgated
under the United States Securities Act of 1933, as amended (the
"U.S. Securities Act"). The securities being offered have not been,
nor will be, registered under the U.S. Securities Act or any state
securities laws, and may not be offered or sold in the United
States or to U.S. persons absent registration or an applicable
exemption from such registration requirements.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Corporation develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications, such as the monitoring of oil wells and other
demanding industrial applications.
Except for historical information, this press release may
contain "forward-looking statements" and "forward-looking
information" within the meaning of applicable securities laws that
reflect Opsens' current expectation regarding future events,
including, without limitation the timing and completion of the
Offering. Forward-looking statements contained in this press
release involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance and achievements
of Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements. Opsens expressly disclaims any
intention to update or revise any forward-looking statements and
information whether as a result of new information, future events
or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.